Oculis (OCS) Competitors $17.80 +0.25 (+1.42%) Closing price 04:00 PM EasternExtended Trading$18.12 +0.32 (+1.83%) As of 04:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCS vs. PTGX, APLS, SRRK, MIRM, MOR, NAMS, AMRX, RARE, KYMR, and IMVTShould you be buying Oculis stock or one of its competitors? The main competitors of Oculis include Protagonist Therapeutics (PTGX), Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), MorphoSys (MOR), NewAmsterdam Pharma (NAMS), AMNEAL PHARMACEUTICALS (AMRX), Ultragenyx Pharmaceutical (RARE), Kymera Therapeutics (KYMR), and Immunovant (IMVT). These companies are all part of the "pharmaceutical products" industry. Oculis vs. Its Competitors Protagonist Therapeutics Apellis Pharmaceuticals Scholar Rock Mirum Pharmaceuticals MorphoSys NewAmsterdam Pharma AMNEAL PHARMACEUTICALS Ultragenyx Pharmaceutical Kymera Therapeutics Immunovant Oculis (NASDAQ:OCS) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Do insiders and institutionals hold more shares of OCS or PTGX? 22.3% of Oculis shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 4.9% of Protagonist Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend OCS or PTGX? Oculis currently has a consensus price target of $35.33, suggesting a potential upside of 98.50%. Protagonist Therapeutics has a consensus price target of $67.20, suggesting a potential upside of 19.91%. Given Oculis' higher possible upside, analysts clearly believe Oculis is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.00 Does the media prefer OCS or PTGX? In the previous week, Oculis had 4 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Oculis and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.60 beat Oculis' score of 1.08 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Which has preferable valuation and earnings, OCS or PTGX? Protagonist Therapeutics has higher revenue and earnings than Oculis. Oculis is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculisN/AN/A-$97.43M-$2.64-6.74Protagonist Therapeutics$434.43M8.02$275.19M$0.7080.06 Which has more risk and volatility, OCS or PTGX? Oculis has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.33, suggesting that its stock price is 133% more volatile than the S&P 500. Is OCS or PTGX more profitable? Protagonist Therapeutics has a net margin of 24.88% compared to Oculis' net margin of -13,788.70%. Protagonist Therapeutics' return on equity of 8.12% beat Oculis' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-13,788.70% -92.95% -70.03% Protagonist Therapeutics 24.88%8.12%7.41% SummaryProtagonist Therapeutics beats Oculis on 13 of the 15 factors compared between the two stocks. Get Oculis News Delivered to You Automatically Sign up to receive the latest news and ratings for OCS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCS vs. The Competition Export to ExcelMetricOculisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$777.18M$3.11B$5.74B$9.56BDividend YieldN/A2.23%4.53%4.07%P/E Ratio-6.7420.3730.4325.14Price / SalesN/A238.33392.4187.63Price / CashN/A42.3737.0358.50Price / Book9.327.918.956.21Net Income-$97.43M-$54.72M$3.26B$265.38M7 Day PerformanceN/A1.58%1.03%-1.12%1 Month Performance1.71%5.81%4.28%-0.68%1 Year Performance49.08%8.71%28.38%18.92% Oculis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCSOculis3.1126 of 5 stars$17.80+1.4%$35.33+98.5%+46.5%$777.18MN/A-6.742News CoveragePositive NewsPTGXProtagonist Therapeutics1.9812 of 5 stars$53.75+5.2%$67.20+25.0%+35.5%$3.18B$434.43M76.79120Positive NewsAPLSApellis Pharmaceuticals4.513 of 5 stars$23.85-2.1%$34.12+43.1%-31.8%$3.08B$781.37M-13.10770Insider TradeShort Interest ↑SRRKScholar Rock4.4087 of 5 stars$31.46-1.5%$45.14+43.5%+269.1%$3.07B$33.19M-10.81140News CoverageAnalyst ForecastMIRMMirum Pharmaceuticals3.4575 of 5 stars$65.87+9.8%$74.13+12.5%+62.7%$3.01B$336.89M-54.44140Positive NewsHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730Positive NewsNAMSNewAmsterdam Pharma3.5419 of 5 stars$24.37-3.7%$41.20+69.1%+49.8%$2.84B$45.56M-15.044AMRXAMNEAL PHARMACEUTICALS3.2242 of 5 stars$8.84+3.5%$11.60+31.2%+16.2%$2.68B$2.79B884.888,100RAREUltragenyx Pharmaceutical4.6783 of 5 stars$27.39-0.5%$81.50+197.6%-44.6%$2.65B$560.23M-4.951,294KYMRKymera Therapeutics3.0233 of 5 stars$37.68-7.2%$59.11+56.9%-8.9%$2.65B$47.07M-12.15170High Trading VolumeIMVTImmunovant2.9164 of 5 stars$14.76-4.5%$35.33+139.4%-53.0%$2.64BN/A-5.39120 Related Companies and Tools Related Companies PTGX Competitors APLS Competitors SRRK Competitors MIRM Competitors MOR Competitors NAMS Competitors AMRX Competitors RARE Competitors KYMR Competitors IMVT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCS) was last updated on 8/21/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oculis Holding AG Please log in to your account or sign up in order to add this asset to your watchlist. Share Oculis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access